H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Alimera (ALIM) today and set a price target of $2. The company’s shares closed yesterday at $1.07.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -12.3% and a 32.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Alimera is a Moderate Buy with an average price target of $2.38.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.34 and a one-year low of $0.72. Currently, Alimera has an average volume of 96.59K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion.
